article thumbnail

Mariana Oncology to be Acquired by Novartis to Advance Precision Radiopharmaceuticals to Treat Cancer

Imaging Technology

milla1cf Fri, 05/10/2024 - 08:08 May 10, 2024 — Mariana Oncology , a fully integrated biotechnology company pioneering a new era of radiopharmaceutical innovation to treat people with cancer , today announced it will be acquired by Novartis for $1 billion upfront and up to $750 million in potential milestone payments.

article thumbnail

SNMMI Elects Cathy Sue Cutler, PhD, FSNMMI, as President at 2024 Annual Meeting

Imaging Technology

milla1cf Wed, 06/12/2024 - 21:58 June 12, 2024 — Cathy Sue Cutler, PhD, FSNMMI , chair of the Isotope Research and Production Department at Brookhaven National Laboratory in Upton, New York, has been named as president for the Society of Nuclear Medicine and Molecular Imaging (SNMMI).

article thumbnail

Carolyn J. Anderson, PhD, Receives SNMMI 2024 Georg Charles de Hevesy Nuclear Pioneer Award

Imaging Technology

milla1cf Mon, 06/10/2024 - 18:17 June 10, 2024 — Carolyn J. Anderson , PhD, a trailblazer in nuclear medicine, has been named the 2024 recipient of the Georg Charles de Hevesy Nuclear Pioneer Award. Louis , Missouri, where she worked more than 20 years developing PET and radiopharmaceutical therapy agents.

article thumbnail

Blue Earth Therapeutics Announces Promising Results from Preclinical Evaluation of Synergistic Drug Combinations with Radiopharmaceutical 177Lu-rhPSMA-10.1 for Treatment of Prostate Cancer

Imaging Technology

The data were presented in a poster presentation at the American Association for Cancer Research (AACR) Annual Meeting 2024 in San Diego, Calif. drug combinations with the scientific community at the prestigious AACR Annual Meeting 2024,” said David E. Blue Earth Group, Oxford, UK, at the AACR Annual Meeting 2024 on April 7, 2024.

article thumbnail

SNMMI Elects Heather Jacene, MD, as Vice President-Elect at 2024 Annual Meeting

Imaging Technology

SNMMI introduced a new slate of officers during its 2024 Annual Meeting, held June 8-11 in Toronto. “As She will also raise awareness of nuclear medicine’s value to clinical colleagues and patients and will be laser-focused on breaking down barriers to radiopharmaceutical availability, reimbursement, affordability, and funding.

article thumbnail

Perspective Therapeutics Announces Exclusive License Agreement with Mayo Clinic for New Radiopharmaceutical Platform for Prostate Cancer Treatment

Imaging Technology

milla1cf Fri, 01/05/2024 - 11:21 January 5, 2024 — Perspective Therapeutics, Inc. This leading radiopharmaceutical platform provides detailed PET imaging-based diagnosis and dosimetry using long-lived copper-64 ( 64 Cu) for imaging and alpha-particle targeted RPT using lead-212 ( 212 Pb).

article thumbnail

Radionetics Oncology Announces Initiation of Phase 1 Radiopharmaceutical Program Against a Novel Target for Adrenocortical Carcinoma

Imaging Technology

a clinical stage radiopharmaceutical company focused on the discovery and development of novel agents for the treatment of a wide range of oncology indications, is pleased to announce that the first subject has been dosed in its Phase 1 study of 68Ga-R8760. milla1cf Tue, 10/17/2023 - 13:07 October 17, 2023 — Radionetics Oncology, Inc.,